Chronic hypertension pathophysiology: Difference between revisions

Jump to navigation Jump to search
(New page: {{Template:Hypertension}} {{CMG}} '''Associate Editor in Chief''': Firas Ghanem, M.D. and Atif Mohammad, M.D. {{EH}} ==Pathophysiology== Most of the secondary mechanisms associated wit...)
 
No edit summary
Line 5: Line 5:
'''Associate Editor in Chief''': Firas Ghanem, M.D. and Atif Mohammad, M.D.
'''Associate Editor in Chief''': Firas Ghanem, M.D. and Atif Mohammad, M.D.


{{EH}}
==Overview==
While the mechanisms underlying secondary hypertension are well understood, the mechanisms underlying primary or essential hypertension are poorly understood.


==Pathophysiology==
==Time Dependence of Pathophysiology==
Most of the secondary mechanisms associated with hypertension are generally fully understood, and are outlined at [[secondary hypertension]]. However, those associated with essential (primary) hypertension are far less understood. What is known is that [[cardiac output]] is raised early in the disease course, with [[total peripheral resistance]] (TPR) normal; over time cardiac output drops to normal levels but TPR is increased. Three theories have been proposed to explain this:
*[[Cardiac output]] is raised early in the disease course, while [[total peripheral resistance]] (TPR) is normal.
* Inability of the kidneys to excrete sodium, resulting in [[natriuretic]] factors such as [[Atrial Natriuretic Factor]] being secreted to promote salt excretion with the side-effect of raising total peripheral resistance.
* Over time [[cardiac output]] drops to normal levels but TPR is increased. Three theories have been proposed to explain this:
* An overactive [[renin / angiotension system]] leads to [[vasoconstriction]] and retention of sodium and water. The increase in blood volume leads to hypertension.
*: Inability of the kidneys to excrete sodium, resulting in [[natriuretic]] factors such as [[Atrial Natriuretic Factor]] being secreted to promote salt excretion with the side-effect of raising total peripheral resistance.
* An overactive [[sympathetic nervous system]], leading to increased stress responses.
*: An overactive [[renin / angiotension system]] leads to [[vasoconstriction]] and retention of sodium and water. The increase in blood volume leads to hypertension.
It is also known that hypertension is highly heritable and [[polygenic]] (caused by more than one gene) and a few candidate [[genes]] have been postulated in the etiology of this condition.<ref name="polymorphism">{{cite journal |author= Sagnella GA, Swift PA |journal=Current Pharmaceutical Design |title=The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure |year = 2006 |month = June |volume = 12 |issue = 14 |pages = 2221-2234 |id = PMID 16787251}}</ref><ref name="polymorphism2">{{cite journal |author= Johnson JA, Turner ST |journal=Current Opinion in Molecular Therapy |title=Hypertension pharmacogenomics: current status and future directions. |year = 2005 |month = June |volume = 7 |issue = 3 |pages = 218-225 |id = PMID 15977418}}</ref><ref name="polymorphism3">{{cite journal|author= Hideo Izawa; Yoshiji Yamada et al |journal=Hypertension |title=Prediction of Genetic Risk for Hypertension |year = 2003 |month = May |volume = 41 |issue = 5 |pages = 1035-1040 |id = PMID 12654703 | url=http://hyper.ahajournals.org/cgi/content/short/01.HYP.0000065618.56368.24v1}}</ref>
*: An overactive [[sympathetic nervous system]], leading to increased stress responses.
 
==Genetics==
Hypertension is highly heritable and [[polygenic]] (caused by more than one gene) and a few candidate [[genes]] have been postulated in the etiology of this condition.<ref name="polymorphism">{{cite journal |author= Sagnella GA, Swift PA |journal=Current Pharmaceutical Design |title=The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure |year = 2006 |month = June |volume = 12 |issue = 14 |pages = 2221-2234 |id = PMID 16787251}}</ref><ref name="polymorphism2">{{cite journal |author= Johnson JA, Turner ST |journal=Current Opinion in Molecular Therapy |title=Hypertension pharmacogenomics: current status and future directions. |year = 2005 |month = June |volume = 7 |issue = 3 |pages = 218-225 |id = PMID 15977418}}</ref><ref name="polymorphism3">{{cite journal|author= Hideo Izawa; Yoshiji Yamada et al |journal=Hypertension |title=Prediction of Genetic Risk for Hypertension |year = 2003 |month = May |volume = 41 |issue = 5 |pages = 1035-1040 |id = PMID 12654703 | url=http://hyper.ahajournals.org/cgi/content/short/01.HYP.0000065618.56368.24v1}}</ref>


==References==
==References==
Line 18: Line 22:


[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category: Up-To-Date]]
[[Category: Up-To-Date Cardiology]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 22:06, 1 November 2011

Hypertension Main page

Overview

Causes

Classification

Primary Hypertension
Secondary Hypertension
Hypertensive Emergency
Hypertensive Urgency

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor in Chief: Firas Ghanem, M.D. and Atif Mohammad, M.D.

Overview

While the mechanisms underlying secondary hypertension are well understood, the mechanisms underlying primary or essential hypertension are poorly understood.

Time Dependence of Pathophysiology

Genetics

Hypertension is highly heritable and polygenic (caused by more than one gene) and a few candidate genes have been postulated in the etiology of this condition.[1][2][3]

References

  1. Sagnella GA, Swift PA (2006). "The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure". Current Pharmaceutical Design. 12 (14): 2221–2234. PMID 16787251. Unknown parameter |month= ignored (help)
  2. Johnson JA, Turner ST (2005). "Hypertension pharmacogenomics: current status and future directions". Current Opinion in Molecular Therapy. 7 (3): 218–225. PMID 15977418. Unknown parameter |month= ignored (help)
  3. Hideo Izawa; Yoshiji Yamada; et al. (2003). "Prediction of Genetic Risk for Hypertension". Hypertension. 41 (5): 1035–1040. PMID 12654703. Unknown parameter |month= ignored (help)

Template:WH Template:WS